Your browser doesn't support javascript.
loading
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis.
Schilhabel, Anke; Walter, Peter Jonas; Cramer, Paula; von Tresckow, Julia; Kohlscheen, Saskia; Szczepanowski, Monika; Laqua, Anna; Fischer, Kirsten; Eichhorst, Barbara; Böttcher, Sebastian; Schneider, Christof; Tausch, Eugen; Brüggemann, Monika; Kneba, Michael; Hallek, Michael; Ritgen, Matthias.
Afiliação
  • Schilhabel A; Laboratory for Specialized Hematological Diagnostics, Medical Department II, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
  • Walter PJ; Laboratory for Specialized Hematological Diagnostics, Medical Department II, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
  • Cramer P; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, 50924 Cologne, Germany.
  • von Tresckow J; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
  • Kohlscheen S; Laboratory for Specialized Hematological Diagnostics, Medical Department II, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
  • Szczepanowski M; Laboratory for Specialized Hematological Diagnostics, Medical Department II, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
  • Laqua A; Laboratory for Specialized Hematological Diagnostics, Medical Department II, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
  • Fischer K; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, 50924 Cologne, Germany.
  • Eichhorst B; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, 50924 Cologne, Germany.
  • Böttcher S; Hematology, Oncology, Palliative Care, Clinic for Internal Medicine III, Rostock University Medical School, 18057 Rostock, Germany.
  • Schneider C; Department III of Internal Medicine, Ulm University, 89081 Ulm, Germany.
  • Tausch E; Department III of Internal Medicine, Ulm University, 89081 Ulm, Germany.
  • Brüggemann M; Laboratory for Specialized Hematological Diagnostics, Medical Department II, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
  • Kneba M; Laboratory for Specialized Hematological Diagnostics, Medical Department II, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
  • Hallek M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, 50924 Cologne, Germany.
  • Ritgen M; Laboratory for Specialized Hematological Diagnostics, Medical Department II, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
Cancers (Basel) ; 14(19)2022 Oct 07.
Article em En | MEDLINE | ID: mdl-36230840
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article